Quest Diagnostics’ Haystack Oncology subsidiary, in collaboration with Lisata Therapeutics, Inc., has made a groundbreaking move in the fight against cancer. By harnessing the power of Haystack’s MRD (minimal residual disease) technology, the duo is set to revolutionize the detection of circulating tumor DNA (ctDNA) for metastatic pancreatic cancer treatment.
This endeavor builds on the successful validation of the Haystack MRD test by Quest Diagnostics in March 2024. With the Haystack MRD Early Experience Program already attracting nearly 20 top cancer institutions, the upcoming nationwide roll-out of the clinical test holds immense promise.
Exploring Lisata Therapeutics’ Innovations
Lisata Therapeutics, a pioneering pharmaceutical company specializing in advanced solid tumors and other major diseases, boasts a lead product candidate, certepetide. This investigational drug is designed to enhance the efficacy of anti-cancer drugs against solid tumors through a novel uptake pathway.
Through its CendR Platform Technology, Lisata has cultivated strategic commercial and R&D partnerships. Exuding confidence in its future, the company foresees significant clinical advancements and achievements on the horizon, with capital to sustain operations until early 2026.
A Deep Dive into the Research Collaboration
The current FORTIFIDE study, evaluating certepetide plus chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients, elucidates an urgent need in the battle against pancreatic cancer. With over 66,000 new cases projected in 2024 and limited treatment success rates, early and accurate detection is paramount.
By leveraging Haystack’s MRD technology to monitor ctDNA levels during the study, the research aims to offer swift insights into certepetide’s therapeutic impact. This strategic alliance underscores the pivotal role of Haystack MRD in propelling novel cancer treatments forward with unprecedented precision.
Industry Insights and Endless Possibilities
The global MRD testing market, valued at $1.2 billion in 2022, is poised for a remarkable CAGR of 14% by 2027. This growth trajectory is fueled by the escalating incidence of cancer and hematological malignancies.
Strategic Collaborations Shaping the Future
Haystack Oncology’s prior partnerships with industry players like TriSalus Life Sciences and Ultima Genomics foreshadow a future teeming with innovation. These alliances underscore Quest Diagnostics’ commitment to advancing cutting-edge technologies in the clinical and biopharmaceutical realms.
An Investor’s Lens: Price Performance and Stock Analysis
Although DGX shares faced a 2.8% decline amid a 11% industry upsurge in the past year, the company continues to hold a promising Zacks Rank #2 (Buy) status.
Noteworthy stocks like Globus Medical and Hims & Hers Health, with Zacks Rank #1 (Strong Buy) and Zacks Rank #2 respectively, offer solid investment opportunities in the thriving medical landscape.
With transformative innovations on the horizon and a commitment to propelling cancer research forward, Quest Diagnostics’ Haystack Oncology and Lisata Therapeutics stand at the vanguard of a new dawn in oncology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.